US stock · Healthcare sector · Diagnostics & Research
Company Logo

CareDx, Inc

CDNANASDAQ

12.79

USD
+0.08
(+0.63%)
Market Closed
-13.51P/E
-98Forward P/E
-0.67P/E to S&P500
684.742MMarket CAP
- -Div Yield

CareDx, Inc

NASDAQ:CDNA

RECENT
PRICE

12.79

P/E
RATIO

-13.51

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-0.67

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.02 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 11/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

- -

- -

- -

- -

- -

- -

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

2.77

(0.69)

(0.26)

- -

3.00

(0.48)

(0.09)

- -

4.70

0.13

(0.70)

- -

2.37

(1.16)

(0.92)

- -

2.46

(2.39)

(1.03)

- -

2.07

(2.38)

(0.62)

- -

2.15

(1.31)

(0.32)

- -

3.01

(0.52)

(0.15)

- -

4.13

(0.40)

0.50

- -

5.63

(0.58)

(0.75)

- -

5.99

(1.41)

(0.98)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

0.02

(19.97)

0.01

(20.44)

0.13

7.10

0.10

2.49

0.03

1.18

0.01

(0.26)

0.20

2.69

0.08

2.35

0.22

5.97

0.38

8.84

0.45

8.48

CAPEX per share

Book Value per share

- -

- -

- -

- -

- -

- -

7

7

6

12

16

23

36

42

46

53

53

Comm.Shares outs.(m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

60.0

3.3

- -

(5.1)

(0.3)

- -

(1.9)

(0.1)

- -

(1.3)

(0.1)

- -

(11.9)

(0.5)

- -

(54.5)

(2.2)

- -

(87.1)

(2.3)

- -

(122.0)

(4.1)

- -

(13.5)

(0.7)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/9/22 | Q3)

Total liabilities
$108 m.

Total assets
$545 m.

Long-term debt
$35 m.

Cash and equiv.
$83 m.

Goodwill $38 m.

Retained earnings $(441) m.

Common stock 53 m. shares

Market Capitalisation
$685 m. (as of 27/11/22)

- -

- -

20

(11.5)%

22

(3.9)%

27

4.6%

28

(42.4)%

41

(91.9)%

48

(42.0)%

77

(20.3)%

127

(19.3)%

192

(11.7)%

296

(10.0)%

319

(23.1)%

Revenue (m)

Operating margin

- -

- -

1

(5)

1

(4)

1

1

1

(14)

3

(39)

4

(55)

4

(47)

6

(22)

10

(19)

12

(31)

15

(74)

Depreciation (m)

Net profit (m)

- -

- -

- -

(24.7)%

- -

(16.0)%

208.6%

2.9%

- -

(48.7)%

3.9%

(97.1)%

3.0%

(114.8)%

3.0%

(61.1)%

8.3%

(17.3)%

5.2%

(9.7)%

4.4%

(10.3)%

1.0%

(23.3)%

Income tax rate

Net profit margin

- -

- -

- -

1

13

(147)

1

11

(151)

29

5

41

24

13

29

(14)

1

19

(16)

18

(6)

62

- -

96

37

- -

99

204

16

278

356

17

466

318

35

437

Working capital (m)

Long-term debt (m)

Equity (m)

- -

- -

- -

(68.5)%

(23.9)%

3.4%

(61.1)%

(14.1)%

2.4%

(3.0)%

2.3%

1.9%

(26.6)%

(21.8)%

(46.5)%

(105.8)%

(51.3)%

(202.6)%

(123.0)%

(61.5)%

904.3%

(38.8)%

(34.0)%

(48.7)%

(18.8)%

(15.8)%

(22.2)%

(6.3)%

(5.4)%

(6.7)%

(6.3)%

(5.7)%

(6.6)%

(15.5)%

(13.7)%

(17.0)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

38

135

348

Receivables

24

35

60

Inventory

6

10

17

Other

4

4

8

Current assets

72

273

433

Acc. Payable

6

10

13

Debt due

3

2

4

Other

26

58

60

Current liab.

35

69

77

- -

- -

100.0%

- -

100.0%

- -

100.0%

961.2%

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

CareDx, Inc (US) started trading on July 4, 2014 (cik: 0001217234), operates in the Healthcare sector (Diagnostics & Research industry), has 633 full-time employees, and is led by Dr. Peter Maag. CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

57.47%

36.43%

Cash flow

-204.14%

-15.55%

Earnings

-4.92%

-199.81%

Dividends

- -

- -

Book value

-353.10%

-192.39%

Insider trading

Type

Shares

Date

Bickerstaff George

Exempt

15,000

11/23/22

Bickerstaff George

Exempt

15,000

11/23/22

Seeto Reginald

InKind

954

11/02/22

Ronai Abraham

InKind

2,492

10/06/22

Ronai Abraham

InKind

1,664

10/06/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

38

42

53

59

192

2021

67

74

76

79

296

2022

79

81

79

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(0.13)

(0.14)

(0.06)

(0.08)

-0.40

2021

(0.01)

(0.04)

(0.23)

(0.31)

-0.58

2022

(0.37)

(0.41)

(0.32)

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -